OCV congratulates Dr. Chris Bostick on receiving the Biocom Life Science Catalyst Award.
Chris is a General Partner at OCV Partners with over a decade of interdisciplinary research experience. Chris joined OCV in 2018 and has provided his expertise and leadership to all of OCV’s healthcare investments as well as contributing to many of OCV’s non-healthcare investments. Chris Co-led investments including Praxis Precision Medicines (NASDAQ:PRAX), Finch Therapeutics (NASDAQ:FNCH), Precision Biosciences (NASDAQ:DTIL), and Rad AI. Chris currently serves on the board of directors of Rad AI and is a board observer for Ossio and TORL Biotherapeutics.
Prior to OCV, Chris completed postdoctoral work at the Institute for Genomic Medicine at Columbia University where he studied precision medicine-based approaches for treating genetic neurological disorders. Before that, he completed research for his Ph.D. spanning drug metabolism, bioelectronics/biosensors, and nanotechnology. He has a broad interdisciplinary background including publications in top journals across Drug Metabolism, Physics, Neuroscience, and Chemistry. Chris holds a B.S. in Biology with a minor in Business from Cornell University and a Ph.D. in Pharmacological and Pharmaceutical Sciences from West Virginia University.
Full profile and award details originally featured here: https://www.businesswire.com/news/home/20211026005405/en/Biocom-California-Announces-Sixth-Annual-Life-Science-Catalyst-Award-Winners